Table 2. Clinical-pathological parameters of the study groups.

Variable	Group PCa1a		Group PCa2b		MSP groupc	Combined PCa1 & PCa2 group
	PCa (N = 55)	NPT (N = 12)	PCa (N = 53)	NPT (N = 24)	PCa (N = 114)	PCa (N = 108)
Mean age, years	62.1	61.5	58.4	61.5	60.5	60.3
Tumor stage, N
pT2	36		34		75	70
pT3	19		19		39	38
ISUP Gleason grading group, N
G≤2	47		36		92	83
G≥3	8		17		22	25
BCR, N
Yes	18		16		32	34
No	35		33		74	68
Unknown	2		4		8	6
Mean follow-up time, months
Mean	51		28		32	41
Median	54		27		29.5	37
Range	[1; 84]		[1; 72]		[1; 84]	[1; 84]
TMPRSS2-ERG status, N
Positive	36		36		76	72
Negative	19		15		36	34
Unknown	0		2		2	2
Mean preoperative PSA level, ng/ml	11.46		10.18		10.89	10.82

BCR – biochemical recurrence; ISUP – International Society of Urological Pathology, MSP – methylation-specific PCR, NPT – non-cancerous prostate tissue, PCa – cancerous prostate tissue, PSA – prostate-specific antigen.

a – Samples were used for gene expression analysis by custom design TaqMan Low Density Arrays (TLDA).

b – Samples were used for gene expression analysis by TaqMan single assays.

c – Samples were used for MT1E gene promoter methylation analysis by MSP.